Evaluating the role of presepsin levels in ascites for patients with chronic liver failure
Predictive Values of Presepsin Levels in ASciteS in Patients With Chronic Liver Failure
This study is testing if measuring a substance called presepsin in the fluid from the abdomen can help doctors predict infections and outcomes for patients with chronic liver failure.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Carol Davila University of Medicine and Pharmacy Academic / other |
| Locations | 1 site (Bucharest) |
| Trial ID | NCT06224023 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the predictive value of presepsin levels in ascitic fluid among newly admitted patients suffering from chronic liver failure. Presepsin, a fragment of CD14, is involved in the inflammatory response to bacterial infections and has been previously linked to early diagnosis of infections and mortality prediction in liver cirrhosis. The study will involve measuring presepsin levels in ascitic fluid to determine its prognostic significance in this patient population. The findings could enhance clinical decision-making regarding the management of patients with chronic liver failure and ascites.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old with ascites and chronic liver failure who can provide informed consent.
Not a fit: Patients who have contraindications to paracentesis or cannot provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a reliable biomarker for predicting outcomes in patients with chronic liver failure and ascites.
How similar studies have performed: Previous studies have shown promising results regarding the use of presepsin as a diagnostic and prognostic tool in similar patient populations.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * patient with ascites and chronic liver failure * no contraindications and technical possibility to perform diagnostic paracentesis * age above 18 years old * informed consent Exclusion Criteria: * contraindications to paracentesis or technical impossibility to perform paracentesis * absence of informed consent
Where this trial is running
Bucharest
- "Agrippa Ionescu" Hospital — Bucharest, Romania (Recruiting)
Study contacts
- Study coordinator: Mihai Ciocirlan
- Email: ciocirlanm@yahho.com
- Phone: 0040722322625
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.